Evaluating The Safety and Effectiveness of The NeoDisc™ Versus ACDF in Subjects With Single-Level Cervical Disc Disease

Inclusion Criteria: * 18-60 years of age (inclusive and skeletally mature) * Diagnosis of symptomatic cervical disc disease, defined as image- confirmed pathology: herniated disc, spondylosis, and/or loss of disc height. Spondylosis is defined as MRI or CT-confirmed disc dessication, loss of disc height, bridging osteophytes, and/or uncovertebral arthrosis. Loss of disc height is specified as a measurement of at least 25% less than an adjacent nonsymptomatic level, but with a minimum of 1mm height remaining. * Functional neurological deficit (i.e., exhibits at least one sign associated with cervical level to be treated, including abnormal reflex, decreased motor strength, abnormal dermatome sensitivity, or pain in a dermatomal distribution) * Symptomatic level is C3-4, C4-5, C5-6 or C6-7 (one level) * Preop NDI ≥30 points * Unresponsive to conservative treatment for ≥6 wks, or exhibits progressive symptoms or signs of nerve root or spinal cord compression in the face of conservative treatment * Not pregnant, nor interested in becoming pregnant within the follow-up period of the study * Willing and able to comply with the requirements defined in the protocol for the duration of the study * Signed and dated Informed Consent Exclusion Criteria: * Prior cervical fusion surgery at the operative level * Prior cervical laminectomy at the operative level (prior cervical laminotomy need not be excluded) * Prior cervical complete facetectomy at the operative level * Requiring surgic…